The objective is to compare the safety and efficacy of masitinib to placebo in patients with documented Smouldering or Indolent Systemic mastocytosis with severe handicap Primary endpoint: Cumulative response by patienthandicap
Data and Resources
- A 24-week with possible extension prospective multicentre randomized double blind placebo-controlled 2-parallel group with a randomization 1:1 Phase 3 study to compare efficacy and safety of masitinib at 6 mgkgday to placebo in treatment of...json
The objective is to compare the safety and efficacy of masitinib to placebo...
|Release Date|| |
|Public Access Level|| |